Background: Clec9a (also named as DNGR-1), is a restricted DAMPs (Damage-Associated Molecular Patterns) receptor that recognizes cell death signals expressed on human BDCA3 +DC and mouse CD8α + and CD103 + DC. With the rapid advancement of immunology, numerous studies of Clec9a have been published. However, no relevant bibliometric studies have been published to date. This study aims to provide a comprehensive understanding of the current state of research and identify potential new research directions via a bibliometric analysis of Clec9a. Methods: Publications related to Clec9a from 2008 to 2024 were retrieved by the Web of Science Core Collection (WoSCC). The three software (VOSviewer, CiteSpace and Bibliometrix) are to assess the contribution and co-occurrence relationships of various countries, institutions, journals and authors, and to explore research hotspots and future trends in this field. Results: A total of 240 English articles from various countries published between 2008-2024 were identified, with an increasing trend in the number of publications each year. The top three contributing countries were USA, Australia, and UK, accounting for 22.50%, 21.25%, and 20.00%, Respectively. The University of Melbourne contributed the most with 32 papers (13.33%). Lahoud, Mireille H, with 32 articles, ranked first amongst authors in terms of publications and Sancho, D. with 188 co-citations, was the amongst co-cited authors. Frontiers in Immunology was influential academic journal in Clec9a research. The aggregation and identification of key nodes in the co-citation network revealed a shift in the focus of Clec9a research. Initially, the hotspot areas were primarily ”antibody formation,” ”systems biology,” ”BDCA3,” and ”langerin,” while in recent years, the focus has shifted to ”vaccines” and ”autophagy.” Conclusion: This is the first bibliometric study to provide a comprehensive summary of the research trends and developments of Clec9a. Currently, the most active frontiers focus on better understanding the role and clinical applications of Clec9a in tumor immunotherapy and DC-targeted vaccination in viral diseases.